Original Article
The rs9909659G/A polymorphisms of the STAT3 gene provide prognostic information in acute myeloid leukemia
Abstract
Background: The signal transducer and activator of transcription 3 (STAT3) is one of the most prominent predictable factors for cancer and leukemia. This study aimed to investigate the relationship between STAT3 gene polymorphisms and the treatment outcome of acute myelogenous leukemia (AML) in a Chinese population.
Methods: A total of 152 AML patients were included in our study, and the therapeutic effects were evaluated. Two single nucleotide polymorphisms (SNPs) in the STAT3 gene (rs9909659G/A and rs17886724T/C) were genotyped. SNP genotyping was performed using the MassARRAY system (Sequenom) via matrix-assisted laser desorption ionization time-of-flight mass spectrometry.
Results: The results illustrated that the frequency of the TC/CC genotype of rs17886724 was higher in the unfavorable group than that of the T/T genotypes (P=0.004). Meanwhile, the C allele in rs17886724 was more frequently classified into the unfavorable group (P=0.023). Age and gender classifications were similar for different rs9909659 genotypes. Patients with M7, low hemoglobin, unfavorable cytogenetic factor, unfavorable gene mutation factor, and high lactate dehydrogenase (LDH) were associated with the GA/AA genotype in rs9909659 (P=0.031, P=0.000, P=0.000, P=0.019, and P=0.001, respectively). Patients with the GA/AA genotype of rs9909659 suffered from poor treatment, including unfavorable cytogenetic and poor response (P=0.001 and P=0.038, respectively). Clearly, AML patients with the GA/AA genotype of rs9909659 were not sensitive to standard chemotherapy.
Conclusions: The rs9909659G/A polymorphisms of the STAT3 gene could be used to predict the treatment outcome in AML patients.
Methods: A total of 152 AML patients were included in our study, and the therapeutic effects were evaluated. Two single nucleotide polymorphisms (SNPs) in the STAT3 gene (rs9909659G/A and rs17886724T/C) were genotyped. SNP genotyping was performed using the MassARRAY system (Sequenom) via matrix-assisted laser desorption ionization time-of-flight mass spectrometry.
Results: The results illustrated that the frequency of the TC/CC genotype of rs17886724 was higher in the unfavorable group than that of the T/T genotypes (P=0.004). Meanwhile, the C allele in rs17886724 was more frequently classified into the unfavorable group (P=0.023). Age and gender classifications were similar for different rs9909659 genotypes. Patients with M7, low hemoglobin, unfavorable cytogenetic factor, unfavorable gene mutation factor, and high lactate dehydrogenase (LDH) were associated with the GA/AA genotype in rs9909659 (P=0.031, P=0.000, P=0.000, P=0.019, and P=0.001, respectively). Patients with the GA/AA genotype of rs9909659 suffered from poor treatment, including unfavorable cytogenetic and poor response (P=0.001 and P=0.038, respectively). Clearly, AML patients with the GA/AA genotype of rs9909659 were not sensitive to standard chemotherapy.
Conclusions: The rs9909659G/A polymorphisms of the STAT3 gene could be used to predict the treatment outcome in AML patients.
